

The below page is an internal, confidential TAP memo which was made public in the Oversight Hearings of the Commerce Committee, headed by Chairman Bliley in 2000, which investigated TAP's profit scheme. TAP's "Return [of money] To [the doctor's] Practice" (RTP) in exchange for 'prescribing' lupron details how much money the doctor can make by putting patients on, or switching patients to, Lupron.

The below page, "Attachment 8", was formerly found at:

<http://com.notes.house.gov/oversight/8.pdf>

As Dr. Redwine's statement, and the below confidential TAP memo illustrate: Profit, rather than patient safety, is THE concern.



# *Increasing Income by adopting Uniformity.....using Lupron*

- ❖ If all patients were on Lupron using the aforementioned scenario, you'd be utilizing 60 vials of Lupron per month.

The return to practice would look like this:

AWP: \$496.25  
AP: \$361.62  
RTP: \$134.63  
x 65 patients  
\$8,750.95 / month  
x 12 months  
\$105,011.40 annually